A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Abstract Background Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab. Methods This pivotal phase III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS), and secondary endpoints were objective response rate (ORR) by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS). Results Enrolled were 256 patients at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination versus control arm (hazard ratio, 1.20; 95% CI: 0.91–1.59; P = 0.19) and ORR was 27.3% versus 21.9% (P = 0.26). A higher rate of grades 3–5 adverse events was reported in the combination arm (67% vs 40%), mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a posttreatment febrile reaction. Conclusions In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results. Clinical trials registration NCT02511405

[1]  P. Wen,et al.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study , 2019, Neuro-oncology.

[2]  I. Barshack,et al.  Abstract 4979: Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors , 2019, Immunology.

[3]  B. Monk,et al.  Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings , 2019, Gynecologic Oncology.

[4]  M. Birrer,et al.  Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect. , 2019, Journal of Clinical Oncology.

[5]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[6]  Raymond Y Huang,et al.  Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma , 2018, Neuro-oncology.

[7]  W. Mason,et al.  Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo , 2018, Neuro-oncology.

[8]  T. Mikkelsen,et al.  Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma , 2018, Neuro-oncology.

[9]  T. Cloughesy,et al.  Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma , 2016, Cancer.

[10]  J. D. de Groot,et al.  Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects , 2014, Clinical Cancer Research.

[11]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[12]  Benjamin M Ellingson,et al.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. , 2014, Radiology.

[13]  A. Brenner,et al.  Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[14]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[15]  T. Batchelor,et al.  Antiangiogenic Therapy for Glioblastoma , 2012, Cancer journal.

[16]  Susan M. Chang,et al.  Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.

[17]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Kathleen R. Lamborn,et al.  Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. , 2010, Neuro-oncology.

[19]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Kelly,et al.  Glioma vascularity correlates with reduced patient survival and increased malignancy. , 2009, Surgical neurology.

[21]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Timothy F Cloughesy,et al.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.

[23]  D. Gillespie,et al.  Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas , 2006, Journal of Neuro-Oncology.

[24]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  I. Barshack,et al.  Transcription-controlled gene therapy against tumor angiogenesis. , 2004, The Journal of clinical investigation.

[26]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[27]  A Afek,et al.  Tissue-specific gene therapy directed to tumor angiogenesis , 2001, Gene Therapy.

[28]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[29]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. A. van der Laak,et al.  Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. , 1998, Human pathology.

[31]  P. Black,et al.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.

[32]  D. Harats,et al.  Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. , 1995, The Journal of clinical investigation.

[33]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[34]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[35]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[36]  P. Wen,et al.  Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials , 2017, Neuro-oncology.